Brodie Martin J, Whitehead John
Epilepsy Res. 2006 Jan;68(1):69-73. doi: 10.1016/j.eplepsyres.2005.09.025.
This report describes the concept for a clinical trial that uses carbamazepine as the gold-standard active control for a study of newly diagnosed patients. The authors describe an endpoint including efficacy and tolerability, and a stopping rule that uses a series of interim analyses in order to reach a conclusion as efficiently as possible without sacrificing reliability.
